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On the basis of their localization and functions, tonsillar CXCR5 + CD4 + T cells were designated as T FH cells [10] [11] [12] . A similar CD4 + T cell subset was found in mouse lymph nodes 13 . Profiling of cytokine production and gene expression in human and mouse T FH cells showed that these cells are distinct from T H 1 and T H 2 cells [14] [15] [16] and help B cells mainly by delivering activating signals with the TNF family molecule CD40L and the cytokine IL- 21 (refs. 14,17-20) . In 2009, the transcription repressor Bcl-6 was discovered to be an essential factor for T FH cell generation in vivo in mice [21] [22] [23] , and since then T FH cells have been recognized as an independent T H subset distinct from T H 1, T H 2 and T H 17 cells.
Our knowledge of the biology of T FH cells has increased significantly during the past decade (reviewed in refs. 24, 25) . Like in other fields of immunology, important biological features of T FH cells have been learned of from studies in mouse models, whereas studies of the ontogeny and function of T FH cells in humans have remained relatively limited, mainly because of difficulties in investigating and manipulating T FH cells from human secondary lymphoid organs. Furthermore, there are only two main sources of human T FH cells for research: tonsils from children who have experienced recurrent throat infections but are otherwise healthy, and spleens, generally from cadaveric organ donors. This poses a challenge in investigations of human T FH cells' association with human diseases such as cancer and autoimmunity. Over 60 million years of independent evolution have introduced significant differences in the immune systems of humans and mice. Thus, it is important to address whether conclusions drawn in mouse T FH studies also hold true for human T FH cells. Recent progress in our understanding of the biology of bloodcirculating T FH cells in humans has provided clues on how to determine whether alteration of T FH responses contributes to human diseases. Furthermore, analyses of blood memory T FH cells (and also lymph node cells in some instances) from patients with primary or acquired immunodeficiencies have also provided important insights regarding the development and/or maintenance of T FH cells in humans. Together with in vitro studies aiming at determining the developmental mechanisms of human T FH cells, these studies have started revealing similarities as well as differences between humans and mice.
In this review, we first summarize our current knowledge of the biology of lymphoid organ T FH cells and discuss the similarities and differences between these cells in mice and humans. Then we discuss recent findings on the circulating memory compartment of T FH 33 . Bcl-6 expression in CD4 + T cells is a prerequisite for GC formation [21] [22] [23] . The origin of T FH cells is not restricted to naive cells, and there is some evidence suggesting that other T H subsets including T H 1, T H 2, T H 17 and regulatory T (T reg ) cells may become T FH cells in GCs (reviewed in ref. 25) . This is consistent with the heterogeneity in cytokine expression patterns among GC T FH cells developed under different immunization protocols and by different types of infectious agents (reviewed in ref. 34) .
In mice, GC T FH cells and T FH precursors have been defined largely on the basis of differences in cell surface markers, particularly the expression of CXCR5 and PD-1, which are more highly expressed in GC T FH cells than in their precursors outside GCs. During the acute or early phase following immunization, IL-21 is expressed almost exclusively by CXCR5 hi PD-1 hi GC T FH cells in lymphoid organs 35 . Investigation of T FH cells is, however, no longer restricted to their identification on the basis of phenotypic markers and cytokine secretion; it is now possible to visualize and track GC T FH cells directly with intravital imaging. Such imaging studies have revealed that GC T FH cells display unique cell dynamics: GC T FH cells continuously immigrate and redistribute to other follicles and neighboring GCs 36 , in a manner dependent on high expression of CXCR5 and the trafficking molecule sphingosine-1-phosphate receptor 2 (S1PR2) 37 . Signals derived from interacting B cells induce GC T FH cells to increase intracellular Ca 2+ and their expression of IL-4 and IL-21, which enhance their capacity to promote the growth and differentiation of B cells 38 . A dynamic exchange of GC T FH cells among multiple GCs and bidirectional signals between GC T FH cells and B cells during their cognate interactions likely represent important mechanisms associated with the efficient selection and expansion of high-affinity B cells during GC responses. GC T FH cells exiting GCs rarely remain in the T cell zone or enter the bloodstream (at least while GC responses are actively in progress) 36 , suggesting that GC T FH cells and their precursors display different cell dynamics.
Mouse studies also identified cell subsets important for the suppression of GC response 34 . These suppressors contain Foxp3 + T follicular regulatory (T FR ) cells [39] [40] [41] . Current evidence shows that, at least in mice, T FR cells are differentiated from thymus-derived Foxp3 + regulatory T cells. T FR cells dampen GC responses by limiting the numbers of both T FH and B cells in GCs [39] [40] [41] . Given that mice lacking functional T FR cells favor the accumulation of nonantigen-specific B cells 40 , T FR cells might be specialized in repressing self-reactive B cells in GCs. T FR cells are also likely to be responsible for terminating the GC response 39 . In either case, the balance between T FH and T FR cells in the GC environment likely represents a key factor in the generation of both high-affinity protective antibodies and pathogenic autoantibodies.
T FH subsets in human tonsils
Studies in the early 1980s showed that CD4 + T cells in human tonsillar GCs express CD57 (ref. 42) and that these CD57 + T cells display a limited ability to express IL-2 (ref. 43) . Although early studies suggested that CD57 is a marker for functionally mature GC T FH cells in humans, CD57 is expressed by only approximately 30% of GC T FH cells, and it is also expressed by a fraction (~10%) of CD4 + T cells localized outside GCs 15, 18 . T FH cells in human GCs are currently defined by their high expression of CXCR5, inducible costimulator (ICOS) and T cell inhibitory receptor PD-1 (refs. 15, 18, 44) . Of note, ICOS is not a useful marker for defining GC T FH cells in mice, as ICOS expression is largely similar between GC T FH cells and T FH precursors 36 . In human tonsils, Foxp3 + T FR cells within GCs are much rarer than in mice (unpublished observations), and current knowledge on human T FR cells is very limited.
While Bcl-6 is well recognized as a transcription factor defining the T FH lineage, mouse studies show that GC T FH cells contain cells coexpressing Bcl-6 and T-bet (the transcription factor typically expressed by T H 1 cells) 35, 45 . In humans, GC T FH cells in tonsils also contain a subset coexpressing Bcl-6 and RORγt (the transcription factor typically expressed by T H 17 cells), in addition to a subset coexpressing Bcl-6 and T-bet 46 . It remains to be established whether these GC T FH cell subsets and GC T FH cells lacking expression of T-bet or RORγt have distinct functions; nevertheless, this observation suggests that other T H subsets might be able to differentiate into T FH cells in humans, similar to cells in mice. An alternative explanation is that there are developmental paths that are shared between T H 1 and T FH cells and between T H 17 and T FH cells in humans, as also proposed in mice 47, 48 .
Recent data point to the possibility that the development of T FH cells might differ between mice and humans. In humans, the cytokine TGF-β acts with IL-12 and IL-23 to promote the expression of multiple T FH molecules, including CXCR5, IL-21 and Bcl-6 (ref. 46 ), on activated naive CD4 + T cells (Fig. 1) [54] [55] [56] [57] [58] , indicating that Bcl-6 is dispensable for their maintenance. The molecular mechanisms by which blood memory T FH cells maintain their T FH characteristics remain largely unknown and thus represent an important research topic.
Human blood memory T FH cells actually include several populations with unique phenotypes and functions (see ref. 53 for a detailed review). Although staining strategies and markers selected to define blood T FH subsets differ among laboratories, we propose that blood memory T FH cells can be assessed on the basis of the following three sets of parameters: the presence of the chemokine receptors CXCR3 and CCR6; of the immunoregulatory molecule PD-1 and the chemokine receptor CCR7; and of the costimulatory molecule ICOS (Fig. 2a) .
The first set of parameters defines three major subsets: The second (PD-1 and CCR7) and third (ICOS) sets of parameters define three other subsets: one activated subset (ICOS + PD-1 2+ CCR7 lo ) and two quiescent subsets (ICOS − PD-1 + CCR7 int and ICOS − PD-1 − CCR7 hi ). In healthy subjects ICOS expression is limited to a small population of blood T FH cells; this population substantially increases after vaccination, and thus defines activated memory T FH cells. In mice these cells appear before the formation of GC T FH cells, because deletion of the Sh2d1a gene, encoding the SAP, an adaptor protein essential for the functions of SLAM family receptors, does not affect the formation of this circulating subset but prevents the appearance of terminally differentiated GC T FH cells 58 . ICOS − cells are further divided into PD-1 + cells (~30% of blood memory T FH cells) and PD-1 − cells, both of which lack the expression of Ki67 and thus are in a quiescent state 58, 59 . CCR7 expression by blood memory T FH cells negatively correlates with that of PD-1 (refs. 52,53) .
The matrix combination of the three parameters defines nine blood memory T FH subsets (Fig. 2a) . The activated ICOS + PD-1 2+ CCR7 lo populations within blood memory T FH 2 and T FH 17 cells might represent the most efficient helpers. Among quiescent T FH 2 and T FH 17 subsets, the ICOS − PD-1 + CCR7 int population provides help to memory B cells more promptly than the ICOS − PD-1 − CCR7 hi population 59, 60 , but the ICOS − PD-1 + CCR7 int and ICOS − PD-1 − CCR7 hi T FH 2 and T FH 17 subsets are equally capable of helping naive B cells.
In contrast, blood memory T FH 1 cells lack the capacity to help naive or memory B cells 54, 55, 59, 60 . Therefore, whether blood memory T FH 1 cells represent a subset of memory T FH cells remains controversial. First, upon T cell receptor stimulation, blood memory T FH 1 cells produce CXCL13, a chemokine that is highly expressed by GC T FH cells and whose receptor, CXCR5, is expressed at high levels by B cells 18, 61 . Second, blood memory T FH 1 cells contain antigen-specific memory cells 59 63 . This demonstrates that ICOS is essential for the generation of T FH and GC responses in humans, as shown in mice 64 .
Multiple mouse models show that B cells play a fundamental role in the generation of GC T FH cells by interacting with T FH precursors 25 . This is also the case in humans, as patients with X-linked agammaglobulinemia, who lack mature B cells because of a deficiency of the tyrosine kinase Btk, and those with CVID, who have a significantly reduced number of B cells (<2% in lymphocytes), display significantly reduced frequencies of blood memory T FH cells 65 . Patients with hyper IgM syndrome caused by a deficiency of functional CD40L also show severely impaired GC formation, as well as reduced blood memory T FH cells 63 and memory B cells 66 , which indicates the importance of CD40-CD40L interactions for GC and T FH development in humans, as shown in mice 67 .
SAP-deficient mice show profoundly altered GC reactions and generation of T FH cells 68 , as SAP is required for durable interactions between helper T cells and B cells, a process essential for the maturation of T FH cells 69 . Consistently, patients with X-linked lymphoproliferative disease caused by SAP deficiency show impaired formation of GCs and impaired development of memory B cells 70 . Interestingly, both SAP-deficient mice and human patients with X-linked lymphoproliferative disease show normal frequencies of blood memory T FH cells 58 , suggesting that at least a subset of circulating blood T FH cells develop before GC T FH formation. Furthermore, migration of GC T FH cells into the circulation is limited during the acute phase of the GC response 36, 38 . It remains possible that GC T FH cells and their descendent memory T FH cells in lymphoid organs 39, 40 might start circulating during the termination of the GC response.
In vitro studies have suggested that IL-12 promotes antibody responses in humans via two mechanisms. IL-12 produced by DCs (CD14 + dermal DCs in human skin 71 ) can induce the in vitro differentiation of CD40-activated naive B cells into IgM-producing plasma cells 72, 73 and of naive CD4 + T cells into T FH -like cells 74, 75 . Consistently, children deficient for the IL-12 receptor β1 (IL-12Rβ1) chain, which is shared by the IL-12 and IL-23 receptors, have reduced T FH and GC responses 74 . Thus, in addition to the recent in vitro observation that TGF-β acts as a critical co-factor of IL-12 and IL-23 for the early T FH cell differentiation process in humans 46 , impaired T FH response in IL-12Rβ1 deficiency in vivo provides evidence that IL-12 and IL-23 contribute to the development of T FH responses in humans. Although the frequency of blood memory T FH cells is significantly reduced in subjects with IL-12Rβ1 deficiency during childhood (less than 10 years old), it gradually increases with age and becomes normal in adults. This indicates that the development and/or maintenance of the T FH cell response can be compensated through other pathways and/or cytokines, possibly IL-6, IL-21 and IL-27.
Mutations in the intracellular signaling molecule STAT3 cause most cases of hyper IgE syndrome. People with this syndrome are susceptible to a narrow spectrum of infections linked to defective T H 17 responses and show altered antibody responses with reduced blood memory T FH cells 76, 77 , indicating that STAT3 is required for optimal T FH cell generation in humans. Given that B cell responses to IL-10 and IL-21, cytokines delivering activation signals via STAT3, are severely altered in STAT3-deficient subjects 78 , the reduced number of blood memory T FH cells in STAT3-mutant subjects might be dependent on both B cell-intrinsic and T cell-intrinsic defects. npg r e v i e w for the lack of STAT3. This concept is supported by the finding that STAT3 and STAT4 play largely redundant roles in the expression of T FH molecules by human naive CD4 + T cells exposed to TGF-β 46 .
T FH cells and autoimmunity
The generation of autoantibodies is a hallmark of autoimmune disease. Autoantibodies target a broad range of self-antigens, including nuclear components (such as double-stranded DNA), organ-specific antigens and soluble factors. These autoantibodies can profoundly dysregulate the function of multiple organs or systems through a variety of mechanisms. Autoantibodies result from a breakdown of tolerance mechanisms during B cell development 79 , from T cell-dependent or -independent B cell activation, or as a consequence of somatic mutation and rogue selection within GCs 80, 81 Although T1D has long been thought to be a T cell-driven and organ-specific autoimmune disease, there is now evidence for a pathogenic role for both B cells and antibodies, as well as for T FH cell dysregulation, in T1D etiopathogenesis. B cells are required for diabetes development in the nonobese diabetic (NOD) mouse model of T1D [92] [93] [94] and in the Roquin san/san model 83 . Direct evidence for a pathogenic role of autoantibodies comes from experiments demonstrating protection from diabetes in NOD mice made deficient for activating Fcγ receptors 95, 96 and, conversely, diabetes induction upon passive transfer of antibodies against islet-expressed neo-self-antigens 83, 96 . In line with these observations, it is not surprising that correlations are being described between T FH cells and autoimmune diabetes. In the Roquin san/san model, aberrant T FH response was directly linked with the development of high anti-islet autoantibody titers and T1D 83 . T FH cells were increased in the pancreatic draining lymph nodes of mice that developed autoimmune diabetes 83 , and cells sharing characteristics of T FH cells, but expressing CCR9 instead of CXCR5, have been found in the pancreas of diabetic-prone NOD mice 97 .
T FH cells in human autoimmune diseases
Increased GC response in patients with systemic lupus erythematosus (SLE) was suggested in early studies by an increased frequency of CD27 + CD38 hi somatically mutated antibody-producing plasmablasts in peripheral blood 98, 99 . Because SLE patients display higher frequencies of self-reactive mature naive B cells than healthy controls owing to a defect in the early checkpoint of B cell repertoires 100, 101 , SLE patients seem predisposed to the development of a broader range of autoantibodies than healthy subjects. Whether and how T FH cells contribute to the pathogenesis of human autoimmunity has been unclear, but recent progress in understanding the biology of blood memory T FH cells has rendered the analysis of human T FH responses in the context of autoimmunity feasible.
Since the description of an association between the frequency of CXCR5 + ICOS + and/or CXCR5 + PD1 + circulating T FH cells and the severity of SLE and Sjögren's syndrome 57 , multiple studies have confirmed 102 or refined these findings, providing improved phenotypic characterization (for example, a reproducible association with the CCR7 lo PD-1 +/hi subset 58 ), and extended them to additional autoimmune diseases such as myasthenia gravis 103 , rheumatoid arthritis 104, 105 , autoimmune thyroid diseases 106 and T1D 107 . An increase of ICOS + blood memory T FH cells showed a positive correlation with serum autoantibody titers and disease activity and/or severity in these diseases 57, 58, 104, [106] [107] [108] . These observations suggest that patients with active autoimmune disease display aberrant T FH responses; this can be monitored through assessment of the increase of activated blood memory T FH cells.
Accumulating evidence also indicates that patients with autoimmune disease display an alteration in the balance of blood memory T FH 1, T FH 2 and T FH 17 cells. In patients with juvenile dermatomyositis 55 , adult SLE 109 and Sjögren's syndrome 102 , T FH 1 cells are underrepresented among blood memory T FH cells, whereas T FH 2 and/or T FH 17 cells are overrepresented. Such alterations were found npg r e v i e w to correlate with disease activity, serum autoantibody titers and/or the frequency of blood plasmablasts 55, 102, 109 . Furthermore, although multiple sclerosis (MS) is not generally considered an autoantibodymediated autoimmune disease, patients with MS also show the same alteration (low T FH 1 and high T FH 17) in the composition of blood memory T FH subsets 110 . Two additional lines of evidence also support a pathogenic role of T FH cells in MS. First, B cells are now thought to play a major pathogenic role in MS, as depletion of B cells with anti-CD20 significantly reduces the number of brain inflammatory lesions and halts the development of new lesions 111 . Second, ectopic B cell follicles are formed in the brain lesions of more than 40% of patients with secondary progressive MS, and the development of these structures correlates with disease severity 112 .
Collectively, although definitive evidence is yet to be found, these observations suggest that an increase in activated T FH 2 and/or T FH 17 cell subsets and a decrease of T FH 1 cells within blood memory T FH cells might be common across multiple autoimmune diseases (Fig. 2b) . Such alterations in blood memory T FH cells might reflect an overall increase of efficient helpers that promote the generation of antibodies in lymphoid organs and/or inflammatory sites in patients with autoimmune diseases. However, to date, studies linking human blood memory T FH cells and T FH cells in lymphoid organs and/or ectopic GCs in inflammatory tissues are lacking. T FH cell responses in ectopic GCs might be of considerable importance, as discussed below.
T FH cells in inflamed tissues
Inflammatory sites in autoimmune diseases often develop lymphoid cell aggregations including helper T cells and B cells, which leads to the formation of well-structured GCs (hereinafter called ectopic GCs). The mechanisms that control the initial development, cellular composition and functional maintenance of ectopic GCs seem to be largely shared with GCs in lymphoid organs 113 . For example, in lupus tubulointerstitial nephritis lesions, T H cells found in lymphoid T and B cell aggregates are phenotypically similar to T FH cells in lymphoid organs 114 . Although the precise mechanisms by which T FH cells accumulate in inflammatory sites in humans remain largely unknown, studies in mouse models suggest the involvement of T H 17 cells 113 . In the experimental autoimmune encephalomyelitis mouse model, T H 17 cells induce the formation of ectopic lymphoid follicles in inflammatory brain lesions via IL-17 and the cell surface molecule podoplanin and show features of T FH cells in these tertiary lymphoid structures 115 . Given that human patients with autoimmune diseases have increased activated memory T FH 17 cells in blood (as discussed earlier), that early developmental pathways for T FH and T H 17 cells in inflammatory environments are shared in humans 46 , and that in mice T H 17-derived IL-17 directly promotes B cell differentiation into GC B cells, which are thought to be the source of pathogenic autoantibodies 116 , it is tempting to speculate that T FH 17 cells might be involved in the formation of ectopic GCs in human autoimmune diseases.
Among patients with autoimmune disease, those with ectopic GCs in inflammatory lesions often have higher disease activity and are refractory to treatment. Yet the formation of ectopic GCs does not simply reflect the extent or the duration of inflammation in the lesions, as only 20% to 40% of patients with chronic inflammation develop ectopic GCs 113 . The formation of ectopic GCs is preceded by aggregates of T and B cells in inflammatory sites. Therefore, at variance with B cell follicles in lymphoid tissues, where autoreactive B cells are excluded because of their reduced expression of CXCR5 (ref. 117) , lymphoid aggregates in inflammatory tissues are likely to be permissive to the entry of autoreactive B cells. Encounters with T FH -like cells at these sites 114 might induce their cell growth and/or differentiation into antibody-producing cells. This possibility is directly supported by the observation that B cells in lymphoid aggregates and/or ectopic GCs produce autoantibodies 113 . Moreover, organ-specific self-antigens are easily accessible by antigen-presenting cells, including B cells, because of the abundance of damaged and/or apoptotic cells caused by the inflammatory process. Therefore, ectopic GCs might represent a major site of autoantibody production in autoimmune diseases, and thus a potentially good target for therapeutics. The nature of T FH cells in inflamed tissues requires further studies. Questions regarding subjects such as the developmental mechanism of T FH cells at inflammatory lesions and how lymphoid aggregates develop into ectopic GCs can be addressed in mouse models, but an effort to determine whether the observations apply to humans will be required. Another important question is whether activated blood memory T FH cells present in active autoimmune disease patients originate from inflammatory lesions. It will be critical to answer these questions in order to directly link the information obtained from the analysis of blood T FH subsets with autoimmune disease pathogenesis.
Genetics of altered T FH cell response
Autoimmune diseases result from complex interplay between genetic and environmental factors. Genome-wide association studies (GWAS) on multiple autoimmune diseases have yielded risk-associated loci 118 (summary at http://www.genome.gov/gwastudies). Variants in HLA class II alleles are at the top of the list of susceptibility loci in most autoantibody-mediated autoimmune diseases, supporting a requirement of CD4 + helper T cells in disease pathogenesis. Importantly, multiple risk-loci identified in autoimmune diseases are potentially associated with the regulation of the development and/or the function of human T FH cells (Fig. 3) . The list includes genes associated with IL-12 and IL-23, as well as cytokines implicated in human T FH cell differentiation 44, 46, 74, 75 , such as IL12A, IL12B (both in multiple sclerosis), IL23R (rheumatoid arthritis), STAT3 (multiple sclerosis), STAT4 (SLE, rheumatoid arthritis, Sjögren's syndrome), IRF5 (SLE, rheumatoid arthritis) and IRF8 (SLE, rheumatoid arthritis, multiple sclerosis). The transcription factors IRF5 and IRF8 positively regulate the production of IL-12 and IL-23 by macrophages and DCs 119, 120 . IRF8 is essential for IL-12 production in humans. IRF8-deficient human subjects experience disseminated infection caused by bacille Calmette-Guérin vaccines, a clinical manifestation also seen in IL-12 receptor deficiency, due to a profound reduction of IL-12 production by monocytes 119 . IRF8 also contributes to signaling in TGF-β, another cytokine important for the generation of human T FH cells 46 , by promoting the expression of TGF-β-activating integrin α v β 8 on the surface of DCs 121 . Studies in SLE and Sjögren's syndrome suggest that the OX40 ligand (OX40L)-coding TNFSF4 might be involved in the generation and/or homeostasis of T FH cells: overexpression of OX40L causes the accumulation of T cells in B cell follicles 122 , and OX40 receptor signals induce CD4 + T cells to express CXCR5 in both mice 26, 123, 124 and humans (unpublished observations). Furthermore, GWAS identified multiple risk-loci encoding molecules expressed by T FH cells, including IL21 (SLE, rheumatoid arthritis) and CXCR5 (multiple sclerosis, Sjögren's syndrome). A recent study showed that in addition to Blimp-1-encoding PRDM1 (ref. 22) , PTPN22, a risk locus identified in GWAS of SLE, rheumatoid arthritis, myasthenia gravis and T1D, negatively regulates the generation of T FH and GC responses in mice 125 . However, whether and how most of these gene variants contribute to aberrant T FH responses in autoimmune diseases remains unknown. The majority of risk loci consist of single-nucleotide polymorphisms within noncoding, putatively regulatory DNA in the proximity of genes 126 , npg r e v i e w suggesting either that there is a disease-causing coding mutation in linkage disequilibrium with the GWAS-identified single-nucleotide polymorphism, or that alteration in pre-and/or post-transcriptional regulation is central to dysregulated immune responses in subjects with autoimmune disease traits. Recent studies aimed at mapping genetic variation contributing to transcriptional variation (termed expression quantitative trait locus mapping studies) through the use of purified immune cell subsets have started to reveal how gene variants regulate immune responses in different cell types [126] [127] [128] . The integration of expression quantitative trait locus mapping with blood memory T FH cells and/or T FH cells within inflammatory tissues and antigen-presenting cells obtained from patients with autoimmune disease might reveal how gene variants identified in GWAS contribute to the aberrant T FH and GC responses.
T FH cells in cancer
Given the demonstrated mutual dependence of T and B cells for growth and survival, it is not surprising that T FH cells play important roles in supporting the growth and survival of follicular B cell tumors. Furthermore, T FH cells themselves can give rise to a peripheral T cell tumor known as angioimmunoblastic T cell lymphoma (AITL). Other peripheral T cell tumors also present with phenotypic features and genetic abnormalities that suggest a T FH origin. Recently, T FH cells were found to infiltrate solid-organ tumors, where they might play both protective and pathogenic roles.
AITL, which accounts for ~20% of peripheral T cell lymphomas (PTCLs), is an aggressive tumor associated with a poor survival rate (33% 5-year survival) 129 . Most patients present with systemic disease associated with lymphadenopathy, hepatosplenomegaly, anemia and hypergammaglobulinemia and suffer from systemic illness. The neoplastic T cells account for only a small fraction of the lymphoid infiltrate and are mixed with a large number of reactive immune cell types, including small lymphocytes, eosinophils and plasma cells, and expansion of follicular dendritic cell networks. Genetic profiling of AITL and immunohistochemical analysis of neoplastic T cells have provided strong evidence that T FH cells are the normal cellular counterpart of the neoplastic cells in AITL, which typically express BCL6, CD10 and other T FH markers, including CXCL13 and PD-1 (ref. 130) . In mice, heterozygosity for a Roquin-1 mutation that causes T cell-autonomous T FH expansion also leads to an AITL-like disease 131 . These mutations have not been found in humans, but mutations in TET2, IDH2, DNMT3A and RHOA are commonly found in AITL [132] [133] [134] . Although the first three genes are known to play a role in DNA methylation and epigenetic modification of gene expression, how these mutations selectively affect T FH cells remains to be understood.
Up to 40% of other PTCLs (PTCLs not otherwise specified (NOS)) also express T FH markers, and some share genetic mutations typically found in AITL, including in TET2, IDH2 and RHOA. For this reason, these tumors are now being referred to as T FH -like PTCL-NOS 135 . The neoplastic T cells of various types of primary cutaneous cell lymphomas also express various T FH cell markers, with the exception of CD10, and in some cases also form rosettes with B cells, which typically occurs in AITL [136] [137] [138] [139] .
Evidence for a pathogenic role of T FH cells in B cell lymphoma first came from studies demonstrating that the number of T cells infiltrating B cell tumors was an important predictor of outcome 140 . Follicular lymphoma, the most frequent indolent non-Hodgkin lymphoma, is thought to originate from GC B cells 141 145 . Foxp3 + T cells that resemble T FR cells described in mice are also present in neoplastic follicles and are expanded during lymphomagenesis 146 , although their significance is still unclear. While overall numbers of tumor-infiltrating Foxp3 + T cells may be associated with improved survival 147 , their follicular localization may be associated with worse survival and increased risk of transformation 148 , perhaps through the dampening of the cytotoxic T lymphocyte-driven anti-tumor response 149 . Recent reports have described increased circulating T FH -like cells in patients with chronic lymphocytic leukemia 150, 151 , particularly during the more advanced stages. These expanded T FH cells may be of pathological relevance, given that the combination of IL-21 and CD40L induces robust chronic lymphocytic leukemia cell proliferation 150, 152 .
In nonlymphoid malignancies, T FH cells are a component of the inflammatory infiltrate of breast cancer, and their presence, as assessed by an eight-T FH gene signature, was associated with increased survival 153 . Moreover, a single T FH -associated gene, CXCL13, conferred the dominant prognostic value. Extensively infiltrated tumors were found to contain tertiary lymphoid structures with visible GCs and CXCL13-producing T FH cells. These findings suggest that T FH cells, by virtue of their ability to secrete CXCL13 and organize ectopic lymphoid filtrates, may be important in coordinating the recruitment of immune cells that mediate the anti-tumor response.
In other tumor types, a high proportion and altered distribution of T FH cells has been reported in colorectal cancer 154 and non-small cell lung cancer 155 60 .
The relationships among viral load, chronicity and numbers of T FH cells are complex. Although most studies have failed to identify a correlation between lymph node T FH cell numbers and viral load 158, 159, 161 , there are possible explanations for the reduction in T FH cells after antiretroviral therapy 160, 162 : the antigen load might control the total number of T FH cells, the compartmentalization of T FH cells between secondary lymphoid tissues and the circulation, or the survival of the blood memory T FH cells. Further work is clearly needed to explain the mechanisms behind these findings.
Chronic HIV infection is associated with an increased frequency of T FH cells in lymph nodes together with increased expression of Bcl-6 (ref. 158) . The expression of IL-6 receptor on T FH cells is increased, which might mediate increased responsiveness to . The importance of IL-6 signals for the maintenance of the T FH response in chronic infection is also highlighted in a mouse model of chronic viral infection with LCMV clone 13 (ref. 168) . Increased T FH generation during chronic HIV infection may in turn affect the host's immune response not only against HIV, but also against other, unrelated viral and bacterial infections 169 . High T FH numbers in HIV-infected individuals correlate with B cell dysregulation, including hypergammaglobulinemia, loss of memory B cells and, occasionally, production of autoantibodies and development of autoimmunity 170 . It is possible that the lowered threshold of B cell selection in GCs due to an excess of T FH cells 171 might lead to the generation of antibodies with low affinities. Alternatively, T FH cell function might be dampened by either T cell-intrinsic factors (e.g., increased sensitivity to IL-6 signaling) 158 or the microenvironment (e.g., increased PD-L1 expression by GC B cells that dampens IL-21 production by T FH cells 162 ).
Designing potent HIV vaccines remains a major challenge. It is now established that antibodies can be protective and prevent infection, as passive transfer of broadly neutralizing antibodies confers protection to HIV challenge in humanized mice infected with HIV 172, 173 . However, most vaccine trials have failed to protect vaccinated individuals to any significant degree. A number of factors associated with HIV make the creation of a decently protective antibody-based vaccine difficult, such as fast mutation rates, structural properties of the envelope complex that make conserved epitopes relatively inaccessible to antibodies, and the need for B cells to undergo extensive somatic mutation to generate broadly neutralizing antibodies. The recent HIV vaccine RV144 "Thai" trial showed that binding of IgG antibodies to envelope proteins is associated with protection, whereas binding of IgA antibodies to envelope proteins correlates directly with the rate of infection 174 . These data suggest a need to better understand the nature and isotype of the antibody response to be elicited by vaccines for protection. There is encouraging evidence that numbers of blood ICOS − PD1 + T FH 2 and T FH 17 cells (but not T FH 1 cells) may serve as a useful biomarker for patients producing broadly neutralizing antibodies to HIV 175 . However, the significant overlap in measurements between high-and low-affinity groups calls for additional studies to further delineate the best correlates of protection. Although numerous studies have concluded that a potent T FH response correlates with antibody titers and protective responses 54, 58, 59 , there is also evidence that an excessive response might be deleterious. Thus, limiting of T FH cells is required for optimal affinity maturation 176 , and an excessive number of T FH cells lowers the threshold for positive selection, allowing survival of low-affinity and self-reactive clones 88 . Furthermore, the balance between T FH and T FR cells is also likely to be important for the overall duration and quality control of GC responses 34 . So far, very little is known about how different adjuvants and prime-boost regime strategies influence the magnitude, longevity and quality of antibody responses. This knowledge will be important for the improved and rational design of protective vaccines.
Conclusions
In the past 5 years considerable progress has been made in the understanding of T FH cells, particularly in humans. We predict that this progress will lead to improved vaccine designs, better management of autoimmune diseases and novel prognostic biomarkers for lymphoid and solid tumors.
